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Abstract
Background: Epigenetic markers might be used for risk-stratifying cancer screening and prevention programs in
the future. Although the clinical utility of consequent epigenetic tests for risk stratification is yet to be proven,
successful adoption into clinical practice also requires the public’s acceptance of such tests. This cross-sectional
online survey study sought to learn for the first time about European women’s perceptions, attitudes, and intended
behavior regarding a predictive epigenetic test for female cancer (breast, ovarian, cervical, and endometrial) risks.
Methods: 1675 women (40–75 years) from five European countries (Czech Republic, Germany, United Kingdom,
Italy, Sweden), drawn from online panels by the survey sampling company Harris Interactive (Germany), participated
in an online survey where they first received online leaflet information on a predictive epigenetic test for female
cancer risks and were subsequently queried by an online questionnaire on their desire to know their female cancer
risks, their perception of the benefit-to-harm ratio of an epigenetic test predicting female cancer risks, reasons in
favor and disfavor of taking such a test, and their intention to take a predictive epigenetic test for female cancer
risks.
Results: Most women desired information on each of their female cancer risks, 56.6% (95% CI: 54.2–59.0) thought
the potential benefits outweighed potential harms, and 75% (72.0–77.8) intended to take a predictive epigenetic
test for female cancer risks if freely available. Results varied considerably by country with women from Germany
and the Czech Republic being more reserved about this new form of testing than women from the other three
European countries. The main reason cited in favor of a predictive epigenetic test for female cancer risks was its
potential to guide healthcare strategies and lifestyle changes in the future, and in its disfavor was that it may
increase cancer worry and coerce unintended lifestyle changes and healthcare interventions.
Conclusions: A successful introduction of predictive epigenetic tests for cancer risks will require a balanced and
transparent communication of the benefit-to-harm ratio of healthcare pathways resulting from such tests in order
to curb unjustified expectations and at the same time to prevent unjustified concerns.
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Background
Cancer is a leading cause of mortality worldwide, account-
ing for 14.1 million new cases and 8.2 million deaths in
2012. [1] Prevention and early detection remain the key in-
terventions to reduce the global cancer burden, although
with modest efficacy. [2–5] Almost all cancers occur
against a background of individual risk factors including
genetic and nongenetic factors. In the last decade, it has
been recognized that expressions of cancer-associated
genes in the majority of sporadic cancers is actually con-
trolled by deoxyribonucleic acid (DNA) methylation pro-
cesses—defined as epigenomics—that can influence gene
expression, without causing a permanent alteration in a
gene (or DNA). The epigenome is highly dynamic. Epige-
nomic regulators are at work nonstop, removing or adding
chemical marks that allow for transient gene readouts
while blocking them in the next minute. Risk factors such
as age, reproductive and lifestyle factors, and environmen-
tal exposures can trigger alterations in the epigenome,
which have been implicated in the development and pro-
gression of cancer. [6] As a consequence, alterations of the
epigenome have become the promising target in recent re-
search endeavors for predicting an individual’s cancer risk;
it is hoped that the information on individual’s cancer risk
may help clinicians offer a more risk-tailored cancer
screening and prevention management that will reduce
cancer burden more effectively. In the setting of prostate
cancer, for example, targeting screening to men at
higher than population average risk could reduce the
proportion of men likely to be overdiagnosed and,
consequently, overtreated. [7, 8] Risk prediction
models that incorporate epigenetic markers could thus
provide new opportunities for risk stratification in
risk-stratified cancer screening and prevention pro-
grams. [6]
The ongoing FORECEE (female cancer prediction using
cervical omics to individualize screening and prevention)
project is developing an epigenetic test to predict the risk
for breast, ovarian, cervical, and endometrial cancers in
women using cervical cells (https://forecee.eu). The clin-
ical utility of this predictive epigenetic test for
risk-stratification in risk-tailored cancer screening and
prevention programs is yet to be assessed. However, even
if in the future studies prove the test’s utility, it needs to
be accepted by the public to be eventually adopted into
clinical practice.
A plethora of studies exists that shed light on the pub-
lic’s knowledge, attitudes, and intended behavior regard-
ing predictive genetic testing, [9, 10] however, to date
nothing is known about these matters regarding predict-
ive epigenetic testing on cancer risk. Because, in contrast
to genetic markers, epigenetic markers act as surrogate
readouts for heritable and lifestyle risk factors, predictive
epigenetic tests may raise questions and concerns among
the public that are different from those raised by genetic
testing (e.g., the “testified” individual’s responsibility for
an increased risk due to a health-impairing lifestyle). A
timely understanding of how the public views predictive
epigenetic testing for cancer risk will therefore help to
carefully guide the development of appropriate commu-
nication tools for the future.
In this study, we investigated whether European
women (i) perceive the potential benefits of predictive
epigenetic testing for female cancer risks to outweigh
the potential harms or vice versa, (ii) want to know their
risk for female cancers, (iii) have personal reasons in
favor and in disfavor of such a test, (iv) intend to use
such a test if available, and (v) whether these percep-
tions, attitudes, and intended behaviors vary by country.
Methods
Study oversight
The study was set up as a cross-sectional population-
based online survey with women from five European
countries that represent Northern, Eastern, Southern,
Western, and Central Europe and the nationalities of
members of the FORECEE consortium. Based on these
criteria the countries chosen were the Czech Republic,
Germany, United Kingdom (UK), Italy, and Sweden. The
design and content of the study was developed by the
authors, discussed in detail with country-specific clinical
partners of the FORECEE consortium (https://forecee.eu),
and revised after feedback. To execute the study online,
the survey sampling company Harris Interactive (Ham-
burg, Germany) was contracted in order to conducted the
online study—including an online version of a leaflet and
an online questionnaire—by using their online panels and
the online panels of Toluna, respectively. Both online
panels—comprising about 78,000 and 275,000 online pan-
elist, respectively—are representative of the general popu-
lation in these countries.
The study was performed in accordance with relevant
guidelines and regulations, and informed consent was
obtained from all participants prior to the study. The
study was approved by the independent Institutional
Ethics Review Board of the Max Planck Institute for
Human Development (Germany).
Sampling procedure and study sample
The goal of the online study was to survey national sam-
ples of women who will likely be the target group for fu-
ture predictive epigenetic tests for female cancer risks
(40 to 75 years) in the Czech Republic, Germany, UK,
Italy, and Sweden. To reduce nonrespondent bias and to
better reflect the general population of women of the
target group in each country, the samples were stratified
based on the official combined distribution of age and
education per country at the point of survey completion.
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Quotas per country were drawn from EUROSTAT
(European Statistical System) [11] and calculated on the
grounds of three levels of education (low, medium, high)
as categorized by the International Standard Classifica-
tion of Education (ISCED) and for four age groups (40–
49 years, 50–59 years, 60–69 years, 70–75 years). We cal-
culated that a sample size of about 300 participants per
country was required to detect differences in perceptions
and intended behavior (2-sided alpha of .05) of 10% or
higher with a 90% power between the national samples.
To allow for nonresponse and ineligibility, in January 2017,
Harris Interactive sent invitation links by email to those of
their female online panelists who matched the selection
criteria in age and nationality. In case, the invitation caught
the interest of an online panelist, she clicked on a link pro-
vided in the invitation email that directed her to the online
portal of Harris Interactive. After providing informed con-
sent, women entered the online study—entirely hosted by
Harris Interactive—which included both the online survey
questionnaire and the online leaflet. After study comple-
tion, the authors of this study received a completely anon-
ymized data sheet from Harris Interactive. Thus, all
respondents of this study are fully anonymous to the
authors.
Of 3629 women contacted by Harris Interactive, 848 did
not respond, 197 were not eligible (duplicate listing, other
strata than originally coded), and 492 entered the online
study after respective quotas were filled. Of the 2092 who
responded, 417 did not finish the online study, resulting
in 1675 completed online surveys. Using the AAPOR
(American Association for Public Opinion Research) re-
sponse rate calculator, [12] which incorporates a default
method for estimating e (estimated proportion of cases of
unknown eligibility that is eligible), the study yielded a
response rate of 61.4% (1675/[1675 + 417 + e (848)]) and a
cooperation rate of 80.1% (1675/[1675 + 417]).
Of the 1675 online surveys collected in total, 356 were
completed in the Czech Republic, 335 in Germany, 323
in the UK, 338 in Italy, and 323 in Sweden. Across
countries, the distribution of age groups was 40–49
years (29.6%), 50–59 years (29.3%), 60–69 years (29.5%),
and 70–75 years (11.7%) and the distribution of educa-
tional levels was low (27.8%), medium (48.8%), and high
(23.5%). 157 women reported a personal history of any
cancer in the past and 104 specifically of female can-
cers. Table 1 provides country-specific details on these
characteristics.
Respondents in each of the national online samples were
similar to their respective general population in terms of
the distribution of age and education, with the following
exceptions: For women from the Czech Republic and
Sweden presenting with low education, the age group “60
to 69 years” were overrepresented and “70 to 75 years”
were underrepresented (Additional file 2: Table S1).
Information leaflet and survey questionnaire
To ensure that all women were equipped with sufficient
background information on predictive epigenetic testing
for female cancer risk, the study was designed as such
that the women entering the online study were first pre-
sented with an online leaflet—whose content they were
advised to familiarize themselves with—before being
subsequently presented with the online survey ques-
tionnaire. While then working through the online sur-
vey questionnaire, women could easily re-approach
Table 1 Characteristics of the study sample
Number of participants (%)
All countries
(N = 1675)
Czech Republic
(n = 356)
Germany
(n = 335)
United Kingdom
(n = 323)
Italy (n = 338) Sweden
(n = 323)
p-value*
Age group (years) .090
40–49 495 (29.6%) 100 (28.1%) 96 (28.7%) 101 (31.3%) 102 (30.2%) 96 (29.7%)
50–59 490 (29.3%) 90 (25.3%) 109 (32.5%) 101 (31.3%) 96 (28.4%) 94 (29.1%)
60–69 494 (29.5%) 131 (36.8%) 82 (24.5%) 82 (25.4%) 101 (29.9%) 98 (30.3%)
70–75 196 (11.7%) 35 (9.8%) 48 (14.3%) 39 (12.1%) 39 (11.5%) 35 (10.8%)
Education (ISCED) <.001
High 393 (23.5%) 52 (14.6%) 65 (19.4%) 116 (35.9%) 43 (12.7%) 117 (36.2%)
Medium 817 (48.8%) 256 (71.9%) 207 (61.8%) 111 (34.4%) 112 (33.1%) 131 (40.6%)
Low 465 (27.8%) 48 (13.5%) 63 (18.8%) 96 (29.7%) 183 (54.1%) 75 (23.2%)
Personal history of female cancer .829
Yes 104 (6.2%) 20 (5.6%) 23 (6.9%) 19 (5.9%) 20 (5.9%) 22 (6.8%)
Unknown 25 (1.5%) 6 (1.7%) 1 (0.3%) 4 (1.2%) 7 (2.1%) 7 (2.2%)
No 1546 (92.3%) 330 (92.7%) 311 (92.8%) 300 (92.9%) 311 (92.0%) 294 (91.0%)
*p-values derived from Chi-Square analysis
Wegwarth et al. BMC Public Health          (2019) 19:667 Page 3 of 11
the content of the online leaflet at any time. The on-
line leaflet (see Additional file 2) included details on
the following aspects:
– Estimates of age-adjusted risks of breast, ovarian,
cervical, and endometrial cancer
– Current approaches of cancer screening and
prevention with examples of the benefit-to-harm
ratio
– Rationale behind predictive epigenetic testing for
female cancer risks and its core principles
– Potential benefit and harms of such predictive
epigenetic testing
– Additional information (e.g., confidentiality of data,
state of evidence)
The development of the online survey questionnaire—
designed to elicit women’s perception, attitudes, and
intended behavior towards predictive epigenetic testing
for female cancer risk—was informed by an assessment
of findings published on these aspects in the field of
genetic testing, in-depth discussions with the clinical
partners and (epi-)genetic experts of the FORECEE con-
sortium group, and by outcomes of focus group discus-
sions with 25 women from Germany and 12 women
from the UK. The survey questionnaire (for the exact
wording, see Additional file 2) first asked four questions
on the core principles of predictive epigenetic testing to
ensure that women had a sufficient basic understanding
of the cancer types targeted by the test, the potential im-
pact of different test outcomes, and the interplay be-
tween external factors and the epigenome. For each of
these four questions, women were presented with a choice
of three answers of which one was correct. Women’s per-
ception of the benefit-to-harm ratio of predictive epigen-
etic testing for female cancer risks was measured by a
5-point-Likert scale reaching from “harms clearly outweigh
potential benefits” to “benefits clearly outweigh potential
harms.” Their desire to learn about their cancer-specific
risk for each of the four cancer types and their intention to
take predictive epigenetic testing for female cancer risks if
the test were freely available were measured by a binary
choice (yes/no). To explore reasons in favor or disfavor of
the test, we presented women with lists of items in favor
(e.g., motivate the adoption of healthier lifestyle) and dis-
favor (e.g., induce unnecessary worry) of predictive epigen-
etic testing that were derived from focus group
discussions with women in Germany and the UK.
Women were asked to tick the reasons that would per-
sonally matter to them and assign ranks of importance
to each (assignment of equal ranks to different reasons
was possible). After women had made their choices on
reasons in favor and disfavor, each woman was again
presented with her chosen reasons and asked if one of
these reasons was so strong that it would outweigh all
the other reasons in favor or in disfavor of the test.
All study materials (online survey questionnaire, on-
line survey leaflet) were translated into country-specific
languages by a professional translation office and checked
for correctness and completeness by country-specific
members of the FORECEE consortium. The survey sam-
pling company Harris Interactive (Hamburg, Germany)
programmed the online version of the survey.
Outcomes and analysis
The online version of the questionnaire did not allow for
item nonresponse, thus all 1675 questionnaires were
completed. Primary outcome measures were (i) women’s
evaluation of the benefit-to-harm ratio of a predictive
epigenetic test for female cancer risks, (ii) women’s de-
sire to know their cancer risk per cancer site, (iii)
women’s reasons in favor of having predictive epigenetic
testing for female cancer risk, (iv) women’s reasons in dis-
favor of having predictive epigenetic testing for female
cancer risk, and (v) women’s intention to use predictive
epigenetic testing for female cancer risks. All results on
the primary outcomes were calculated as absolute propor-
tions with 95% confidence intervals.
Binary and multivariate logistic regression models were
used to investigate whether differences between countries
for each of the primary outcomes were confounded by
covariates such as women’s knowledge of the core princi-
ples of predictive epigenetic testing, their age, their educa-
tion, or their personal cancer history. If not reported
otherwise, none of these variables significantly influ-
enced country-specific differences. Bonferroni correc-
tions were employed to correct for multiple testing, and α
was set at 0.05/5 = .01. All data were stored and analyzed
with IBM SPSS Statistics 24 (New York City, USA). To fa-
cilitate clear and unbiased reporting of our study results,
the STROBE (Strengthening the Reporting of Observa-
tional studies in Epidemiology) reporting guideline was
applied (Additonal file 1: STROBE checklist).
Results
Women’s knowledge of core principles of the predictive
epigenetic test for female cancer risk
Overall, between 57.4% (55.0, 59.8) and 94.6% (95%
confidence interval [CI]: 93.4, 95.6) of women pro-
vided correct responses to each of the four questions
on the core principles of the predictive epigenetic test
for female cancer risk (Table 2). Women were least
likely to correctly respond to the question on how a
lower-than-average risk test result may guide their
cancer screening and prevention management. Women
from the Czech Republic (p < .001) and women with lower
education (p < .001) were more likely to provide lower
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proportions of correct responses on core principles than
women from the other European countries or women
with higher education (Additional file 2: Table S2).
After adjusting for education in multivariate analyses
and multiple testing, the significant association between
country and women’s knowledge of core principles
(p = < .001) remained.
Women’s evaluation of the benefit-to-harm ratio of the
predictive epigenetic test
More than half (56.6, 95% CI: 54.2, 59.0) of all women
felt that the potential benefits of a predictive epigenetic
test for female cancer risks would somewhat or clearly
outweigh its potential harms. This evaluation was shared
by the majority of women within each of the studied
European countries, except by women from the Czech
Republic where the majority thought that the test’s
harms equal its benefits (p < .001) (Fig. 1). After adjust-
ing for covariates (knowledge of core principles, educa-
tion, personal female cancer history, age) and multiple
testing, compared to women from the Czech Republic,
women from the other four countries were on average
only about half as likely to consider the harms of a pre-
dictive epigenetic test for female cancer risks to equal or
to somewhat/clearly outweigh the benefits (Additional
file 2: Table S2).
Also, women with limited knowledge of the test’s core
principles (≤50% correct) evaluated the test more nega-
tively in univariate analyses (p < .001). Multivariate ana-
lysis showed, however, that the association between
women’s benefit-to-harm evaluation and their knowledge
of the test’s core principles was confounded by their
level of education (χ2 (1) = 22.48; p < .001). After adjust-
ing for covariates and multiple testing, women present-
ing with limited knowledge of the test’s core principles
were seen to be nearly 2 times as likely (odds ratio [OR]:
1.79, 95% CI: 1.24–2.25, p < .001) to consider the harms
of the predictive epigenetic test to equal or somewhat/
clearly outweigh the benefits than women presenting
with higher degrees of knowledge (> 50%) (Additional
file 2: Table S2).
Women’s desire to know their female cancer risks
The majority of women (63.6%) said they want to know
their individual risk for each of the four female cancers
(breast, ovarian, cervical, endometrial) (Table 3). Within
each country, women’s desire to know the risk for one
female cancer over the other cancers did not differ
Table 2 Proportion of women’s correct responses on the questions of the core principles of predictive epigenetic testing for breast,
ovarian, cervical, and endometrial cancer risk
Percentage of correct responders (95%CI)
Correct items of the surveyed core principles
of predictive epigenetic
testing for female cancer
risks
All Countries
N = 1675
Czech
Republic
n = 356
Germany
n = 335
United
Kingdom
n = 323
Italy
n = 338
Sweden
n = 323
p-
value*
The predictive epigenetic
test for female cancer risks
targets a woman’s risk for
breast, ovarian, cervical,
and endometrial cancer.
94.6 (93.4,
95.6)
93.5 (90.5,
95.9)
98.5 (96.6,
99.5)
96.0 (93.2,
97.8)
89.1 (85.2,
92.2)
96.0 (93.2,
97.8)
<.001
With a lower-than-
average risk result,
a woman could
consider having less
screening and
consequently may
reduce her likelihood
of overdiagnosis and
false alarms.
57.4 (55.0,
59.8)
43.0 (37.8,
48.3)
57.0 (51.5,
62.4)
81.1 (76.4,
85.2)
62.1 (56.7,
67.3)
44.9 (39.5,
50.5)
<.001
With a higher-than-
average risk result,
a woman could
consider having
more screening or
preventive measure
in order to reduce
her likelihood of
dying from cancer.
76.2 (74.1,
78.2)
47.5 (42.2,
52.8)
83.9 (79.5,
87.7)
87.6 (83.5,
91.0)
76.3 (71.4,
80.8)
88.2 (84.2,
91.5)
<.001
Our environment and
lifestyle is changing
the epigenome of
our cells.
75.3 (73.2,
77.4)
66.3 (61.1,
71.2)
79.1 (74.4,
83.3)
87.3 (83.2,
90.7)
72.8 (67.7,
77.5)
72.1 (66.9,
77.0)
<.001
*p-values derived from Chi-Square analysis
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significantly. Women’s desire differed between countries,
however: Compared to women from the Czech Republic,
women from the UK, Italy, and Sweden were about 2 to
3 times more likely to desire risk information on three
or all female cancers in multivariate analysis (Additional
file 2: Table S2), whereas women from Germany did not
differ from the Czech Republic (p = .122). Also, women’s
age was associated with a higher desire to learn about
the risk for female cancers in univariate and multi-
variate analysis, with women aged 40 to 59 years be-
ing significantly more likely to request such predictive
information on their cancer risk than women older
than that (Additional file 2: Table S2).
Women’s reasons in favor of a predictive epigenetic test
for female cancer risks
When women were presented with the five potential
reasons in favor of taking this epigenetic test, 67.2% of
all women chose all five reasons, 3.9% chose four rea-
sons, 6.4 and 7.3% chose three and two reasons, respect-
ively, and 15.3% chose one reason. Figure 2a shows
women’s ranking of their perceived importance of each
of the reasons in favor of the test. When subsequently
presented with all individually ticked reasons, 817
(48.8%) out of 1675 women indicated that one of these
reasons was so strong that it outweighed all the others.
Among these, the test’s potential to guide the personal
cancer prevention strategy was the most decisive reason
for women in Germany (38.8%), the Czech Republic
(29.1%), and Italy (30.9%), whereas for women in the UK
(37.0%) and Sweden (30.4%), it was its potential to mo-
tivate the adoption of a healthier lifestyle.
Women’s reasons in disfavor of the predictive epigenetic
test for female cancer risks
When presented with the five reasons that might speak
in disfavor of taking the predictive epigenetic test, 61.1%
of all women chose all five reasons, 3.5% chose four rea-
sons, 5.6 and 8.6% chose three and two reasons, respect-
ively, and 21.3% chose one reason. Figure 2b shows
women’s ranking of their perceived importance of each
of the reasons in disfavor of the test. When again
Table 3 Women’s desire to know their 10-year risk of developing breast, ovarian, cervical, and endometrial cancer
Percentage of responders who said they want to know the cancer risk (95% CI)
Want to know their risk for … All Countries
N = 1675
Czech Republic
n = 356
Germany
n = 335
United Kingdom
n = 323
Italy
n = 338
Sweden
n = 323
p-value*
Breast cancer 71.7 (69.5, 73.8) 65.2 (60.0, 70.1) 58.2 (52.7, 63.5) 76.8 (71.8, 81.3) 83.4 (79.0, 87.2) 75.5 (70.5, 80.1) <.001
Ovarian cancer 66.6 (64.3, 68.9) 57.6 (52.3, 62.8) 52.8 (47.3, 58.3) 71.5 (66.3, 76.4) 80.8 (76.2, 84.8) 71.2 (65.9, 76.1) <.001
Cervical cancer 65.7 (63.3, 67.9) 58.1 (52.8, 63.3) 50.7 (45.3, 56.2) 70.0 (64.6, 74.9) 80.5 (75.8, 84.6) 69.7 (64.3, 74.6) <.001
Endometrial cancer 65.0 (62.7, 67.3) 55.6 (50.3, 60.9) 51.0 (45.6, 56.5) 68.7 (63.4, 73.7) 80.2 (75.5, 84.3) 70.3 (65.0, 75.2) <.001
*p-values derived from Chi-Square analysis
Fig. 1 Distribution of women’s evaluation of the benefit-harm-ratio of a predictive epigenetic test for female cancer risks with standard errors
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AB
Fig. 2 Women’s subjective ranking of the importance of reasons in (a) favor and (b) disfavor of a predictive epigenetic test for female cancer risks
(data are pooled across countries)
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subsequently presented with all individually ticked rea-
sons in disfavor of the test, 884 (52.8%) out of 1675
women indicated that one of these reasons was so strong
that it outweighed all the others. That the result of the
test may induce unnecessary worry and reduce quality of
life was the most decisive reason against taking the test
for women in the UK (46.7%) and Sweden (33.5%),
whereas for women in Germany (37.1%) and Italy
(30.9%) it was the test’s potential to cause a woman to
permanently expect the onset of cancer. Women in the
Czech Republic (39.4%), in contrast, were most worried
about the fact that the test result may pressure them
into adopting a healthier lifestyle or to undergo more
cancer screening.
Women’s intention to take the test if it was already available
Overall, 75% of women responded that they would defin-
itely or probably take this epigenetic test if it were freely
available. However, women’s preparedness to take the test
depended on the country they came from (p < .001) and
their initial evaluation of the test’s benefit-to-harm ratio
(p < .001). After adjusting for covariates and multiple test-
ing, women from the Czech Republic, UK, Italy, and
Sweden were about 2 to 3.5 times more likely to consider
taking the test if it were freely available than women from
Germany (Additional file 2: Table S2). Results were con-
founded, however, by women’s evaluation of the test’s
benefit-to-harm (χ2 (1) = 92,67; p < .001), with women
evaluating the test rather negatively being less prepared to
take the test (p < .001). In accordance with this finding, we
found that women who intended to take the test were
also more likely to tick four or all five reasons in favor
of the test than women who said they would definitely
or probably not take the test: 73.7% (71.1, 76.1) versus
63.3% (58.4, 67.9). Likewise, women who indicated that
they would not take the test were more likely to tick four
or all reasons in disfavor of the test than women who
indicated they would take the test: 71.9% (67.3, 76.2)
versus 62.5% (59.8, 65.2).
Discussion
Of the 1675 European women surveyed in our study, al-
most three quarters demonstrated sufficient knowledge
(≥75% correct responses) of the core principles of a pre-
dictive epigenetic test for female cancer risks after read-
ing the leaflet. Within each country, women were least
likely to know, however how the prediction of a
lower-than-average risk for female cancer may impact
their future cancer screening and prevention manage-
ment. We can only speculate about why women particu-
larly struggled with answering this question. For one, the
idea of having less screening may have conflicted with
the conventional wisdom that screening always means
“early caught, successfully fought.” Information that
diverges from established opinion or attitudes is likely to
be ignored. [13] Also, research showed that the concepts
of “overdiagnosis” and “overtreatment” in cancer screen-
ing are hardly known by most people, [14, 15] which is
why some women in our survey may have found it
harder to memorize this unfamiliar information. [16]
The knowledge of core principles also varied between
countries, with women from the Czech Republic being
least likely to correctly answer the questions. The ob-
served variation was confounded by women’s education,
where those with a high degree of education were al-
most 3 times as likely to know at least 75% of the core
principles of the test than women with a low degree of
education.
Women’s knowledge of the core principles had consid-
erable consequences on how women evaluated the
benefit-to-harm ratio of the predictive epigenetic test on
cancer risks: While the majority of women in each coun-
try—except women from the Czech Republic— viewed
the benefit-to-harm ratio positively, women with limited
knowledge (≤50%) of the test’s core principles were likely
to see the harms prevailing. However, this association
between women’s evaluation and their knowledge of the
test’s core principles was confounded by education.
Given that women’s evaluations significantly influenced
women’s intention to take a predictive epigenetic test,
this finding matters. If women with lower levels of edu-
cation decide against having a potentially effective test
(once these are available and have been proven effective
on the basis of solid evidence) because they do not
understand the related health information, then health
disparity may occur. Already now, few leaflets on can-
cer screening, letters of invitation to screenings, and
health websites provide balanced information on screen-
ings’ benefit and harms (e.g., as absolute risk informa-
tion) that would enable women to make an informed
choice. [17–21] Instead, they often refer to relative sta-
tistics, lifetime incidences, 5-year survival rates, or no
numbers at all, all of which contribute to women ser-
iously overestimating their own cancer risk and the
benefit of screening and underestimating the harms.
[22–26] To avoid unreasonably high expectations but
also unfounded misgivings about the new generation of
predictive epigenetic tests, health policy makers and
health care providers need to ensure that clear principles
for the reporting on future predictive epigenetic testing
are in place before the tests enter the health care system.
First guidance for such transparent risk communication
following established reporting principles is already
available. [27–31]
Our survey further sheds light, for the first time, on spe-
cific reasons that drive a positive or negative evaluation.
On the positive side, women appreciate that predictive epi-
genetic tests may help to improve their cancer screening
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and prevention management and, specifically for epigen-
etic testing, may even motivate the adoption of a healthier
lifestyle. On the negative side, they well perceived that re-
ceiving a predictive epigenetic test result could induce per-
manent worries about cancer and pressure them to engage
in lifestyle changes that they had not intended to adopt.
Considering that professionals in the health care system
(e.g., gynecologists) are envisaged to provide the epigenetic
tests for predicting female cancer risks, it will be particu-
larly the responsibility of health care professionals to
address any ambiguity about the test by transparently and
sufficiently counsel women about the test’s accuracy, the
meaning of risk-stratified test results on individual care,
and their impact on the individual’s life and health-related
outcomes. Given the number of studies that document
health professionals’ difficulties in understanding and com-
municating medical risks [32–37] and test statistics [38–
40], clear principles for the counselling on future predict-
ive epigenetic testing need to be also established in training
programs tailored to the healthcare professionals involved
in predictive epigenetic testing. The apparent desire of
many women to learn more about their cancer risk by epi-
genetic risk prediction [41–43] may offer new and more
efficient pathways in the fight against cancer but also
means that the existing communicative and educative
problems documented in cancer screening and prevention
need first to be resolved.
Finally, our survey revealed some country-specific differ-
ences that are hard to explain and about which we can only
speculate. For instance, women from Germany were least
likely to express their intention to have the predictive
epigenetic test on cancer risks, while at the same time
expressing a rather positive evaluation of the benefit-to-
harm-ratio and presenting with sufficient knowledge of the
core principals. One reason for this observation might be
rooted in how German media cover personalized medicine.
Whereas German media provide a relatively conservative
view on such new technology and also point to its potential
shortcomings, media in the UK, for instance, highlight its
potential merits. [44] We also found country-specific varia-
tions in Europeans women’s knowledge of the core princi-
ples, particularly for the questions that interrogated how
lower−/higher-than-average risk results may affect cancer
screening and prevention uptake. Part of this variation
might be influenced by women’s current knowledge and
adherence to individual country policies on screening. All
of the five European countries have implemented the same
population-based screening programs for both breast and
cervical cancers but differ in terms of organizational char-
acteristics (e.g., standardized informational material) and
implementation stage. For instance, women in Germany
and the UK receive a standardized leaflet on benefit and
harms of mammography when being invited to screening,
but women in the Czech Republic and Italy do not. Also,
the intervals of screening differ across countries, such as a
2-year interval in Germany and a 3-year interval in the UK.
However, it goes beyond the scope of this study to examine
to what extent these variations in information politics and
implementation stages influence the reception of informa-
tion on new test opportunities and which cognitive, emo-
tional or structural mechanisms are in place; this question
needs to be clarified in future studies.
Our findings need to be viewed in the light of some lim-
itations. First, we measured women’s intention to take a
predictive epigenetic test and not their actual behavior.
Previous research demonstrated modest correspondence
between people’s reported intention and their actual be-
havior—known as intention-behavior-gap. [45] It is thus
likely that the observed intention to take a predictive epi-
genetic test for female cancer and the potential actual up-
take of such tests in the future will differ from one
another. Second, we used an epigenetic risk prediction test
that is currently under development (Women’s identifica-
tion test/WID test) for four female cancers as an example
for introducing women to such future test opportunities
in the field. Due to its developmental state, we were not
able to provide women with any numerical estimates on
the clinical utility of the test and the likely benefit-to-harm
ratios of epigenetic risk-tailored cancer screening and pre-
vention programs. Such numbers may have had a signifi-
cant impact on women’s evaluation of the benefit-to-harm
ratio and their reported intention to take such a test.
Third, because women in our survey were not offered the
option to include any further reasons in favor and disfavor
for predictive epigenetic testing than the five reasons of-
fered, we cannot exclude the possibility that reasons other
than displayed in our survey have played a role in women’s
evaluation of such a test. Fourth, we cannot rule out the
existence of a nonrespondent bias. Although we achieved
a reasonable response rate and were able to roughly match
women’s characteristics for age and education in the na-
tional samples to the general population at survey comple-
tion, we cannot exclude the likelihood that women with a
higher-than-average cancer risks due to close family his-
tory or those with a greater interest in the topic of cancer
and cancer screening were more likely to respond to our
survey, which might have influenced and limited the
generalizability of our results.
Conclusion
Despite these limitations, our survey is the first to show
how European women evaluate the opportunity to have
their female cancer risks predicted by an epigenetic test,
what this evaluation depends on, and how this evalu-
ation may influence the acceptance of these tests in the
future. Women who are not in a position to sufficiently
understand the actual impact of future predictive epigen-
etic tests on their healthcare might be likely to discard a
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potential viable test opportunity. Their understanding of
and trust in this new technology will largely depend on
how healthcare professionals and healthcare providers in-
form and counsel women in the future. [46] A balanced
and transparent communication of the chances and risks
of predictive epigenetic tests will be required in order to
curb undue hopes but also prevent unjustified concerns
about these forthcoming testing opportunities.
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